NEW YORK ( TheStreet) -- Pain Therapeutics (Nasdaq: PTIE) has been upgraded by TheStreet Ratings from sell to hold. The company's strengths can be seen in multiple areas, such as its solid stock price performance, increase in net income and largely solid financial position with reasonable debt levels by most measures. However, as a counter to these strengths, we find that the company's return on equity has been disappointing.

Highlights from the ratings report include:
  • Return on equity has greatly decreased when compared to its ROE from the same quarter one year prior. This is a signal of major weakness within the corporation. Compared to other companies in the Pharmaceuticals industry and the overall market, PAIN THERAPEUTICS INC's return on equity significantly trails that of both the industry average and the S&P 500.
  • PTIE, with its decline in revenue, slightly underperformed the industry average of 0.2%. Since the same quarter one year prior, revenues slightly dropped by 0.4%. The declining revenue has not hurt the company's bottom line, with increasing earnings per share.
  • PAIN THERAPEUTICS INC reported significant earnings per share improvement in the most recent quarter compared to the same quarter a year ago. This company has reported somewhat volatile earnings recently. But, we feel it is poised for EPS growth in the coming year. During the past fiscal year, PAIN THERAPEUTICS INC reported poor results of -$0.27 versus -$0.08 in the prior year. This year, the market expects an improvement in earnings ($0.26 versus -$0.27).
  • The net income growth from the same quarter one year ago has significantly exceeded that of the S&P 500 and the Pharmaceuticals industry. The net income increased by 79.7% when compared to the same quarter one year prior, rising from -$1.02 million to -$0.21 million.
  • Powered by its strong earnings growth of 100.00% and other important driving factors, this stock has surged by 52.16% over the past year, outperforming the rise in the S&P 500 Index during the same period. Regarding the stock's future course, our hold rating indicates that we do not recommend additional investment in this stock despite its gains in the past year.

Pain Therapeutics, Inc., a biopharmaceutical company, engages in the research and development of novel drugs. Pain has a market cap of $420.3 million and is part of the health care sector and drugs industry. Shares are up 40.9% year to date as of the close of trading on Friday.

You can view the full Pain Ratings Report or get investment ideas from our investment research center.
null

If you liked this article you might like

Ultragenyx Makes Bid for Dimension Therapeutics - Biotech Movers

5 Big-Volume Stocks You Should Stay Away From -- Plus 2 to Buy

For Pain Therapeutics CEO, 3 FDA Rejections Are Worth $23 Million

Pfizer (PFE) Stock Falls After Dropping Pain Drug

Jim Cramer's 'Mad Money' Recap: Next Week's Game Plan